<![CDATA[Biotek-snakken — Februar 2018]]>NUE: https://www.redeye.se/arena/posts/nuevolution-goda-nyheter

]]>https://dev.proinvestor.com/forum/topic/401368/biotek-snakken-februar-2018RSS for NodeMon, 08 Jun 2026 10:31:29 GMTTue, 13 Feb 2018 08:02:17 GMT60<![CDATA[Reply to Biotek-snakken — Februar 2018 on Wed, 21 Feb 2018 09:16:33 GMT]]>http://www.bergenbio.com/investors/reports/webcast1/

]]>https://dev.proinvestor.com/forum/post/8056879https://dev.proinvestor.com/forum/post/8056879Wed, 21 Feb 2018 09:16:33 GMT<![CDATA[Reply to Biotek-snakken — Februar 2018 on Wed, 21 Feb 2018 09:16:31 GMT]]>God præsentation fra BergenBio:

]]>https://dev.proinvestor.com/forum/post/8056881https://dev.proinvestor.com/forum/post/8056881Wed, 21 Feb 2018 09:16:31 GMT<![CDATA[Reply to Biotek-snakken — Februar 2018 on Sat, 17 Feb 2018 15:05:14 GMT]]>http://borsen.dk/nyheder/avisen/artikel/11/191810/artikel.html?utm_source=forside&utm_campaign=nyhed_03

]]>https://dev.proinvestor.com/forum/post/8056880https://dev.proinvestor.com/forum/post/8056880Sat, 17 Feb 2018 15:05:14 GMT<![CDATA[Reply to Biotek-snakken — Februar 2018 on Tue, 13 Feb 2018 22:16:09 GMT]]>EXEL - cabozantinib viser gode fase 2 resultater i thyroid cancer (DTC) https://finance.yahoo.com/news/exelixis-announces-results-phase-2-210500301.html

]]>https://dev.proinvestor.com/forum/post/8056878https://dev.proinvestor.com/forum/post/8056878Tue, 13 Feb 2018 22:16:09 GMT